Safety profile of cabotegravir plus rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the phase 3 FLAIR, ATLAS, and ATLAS-2M studies

被引：0

作者：

de los Rios, P. ^{[1
]}

Patel, P. ^{[1
]}

Huang, J. ^{[2
]}

Harrington, C. ^{[1
]}

D'Amico, R. ^{[1
]}

Thiagarajah, S. ^{[3
]}

Birmingham, E. ^{[4
]}

Van Solingen-Ristea, R. ^{[5
]}

Spreen, W. R. ^{[1
]}

Baugh, B. ^{[6
]}

Bosse, M. ^{[7
]}

机构：

[1] ViiV Healthcare, Res Triangle Pk, NC USA

[2] GlaxoSmithKline, Mississauga, ON, Canada

[3] GlaxoSmithKline, London, England

[4] Janssen Res & Dev, Raritan, NJ USA

[5] Janssen Res & Dev, Beerse, Belgium

[6] Janssen Res & Dev, Titusville, FL USA

[7] ViiV Healthcare, San Diego, CA USA

来源：

HIV MEDICINE | 2021年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

PE2/75

引用

页码：131 / 131

页数：1

共 21 条

[1] Safety profile of cabotegravir plus rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the Phase 3 FLAIR, ATLAS and ATLAS-2M studies
de los Rios, Patricia
Patel, Parul
Huang, Jenny
Harrington, Conn
D'Amico, Ronald
Thiagarajah, Shanker
Birmingham, Eileen
Van Solingen-Ristea, Rodica
Spreen, William R.
Baugh, Bryan
Benn, Paul D.
Bosse, Matthew
HIV MEDICINE, 2022, 23 : 13 - 13
[2] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Rizzardini, Giuliano
Overton, Edgar T.
Orkin, Chloe
Swindells, Susan
Arasteh, Keikawus
Gorgolas Hernandez-Mora, Miguel
Pokrovsky, Vadim
Girard, Pierre-Marie
Oka, Shinichi
Andrade-Villanueva, Jaime F.
Richmond, Gary J.
Baumgarten, Axel
Masia, Mar
Latiff, Gulam
Griffith, Sandy
Harrington, Conn M.
Hudson, Krischan J.
St Clair, Marty
Talarico, Christine L.
Patel, Parul
Cutrell, Amy
Van Eygen, Veerle
D'Amico, Ronald
Mrus, Joseph M.
Wu, Sterling
Ford, Susan L.
Chow, Ken
Roberts, Jeremy
Wills, Angela
Walters, Nicola
Vanveggel, Simon
Van Solingen-Ristea, Rodica
Crauwels, Herta
Smith, Kimberly Y.
Spreen, William R.
Margolis, David A.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
[3] Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results
D'Amico, R.
Orkin, C.
Bernal Morell, E.
Tan, D.
Katner, H.
Singh, Y.
Stellbrink, H.
Belonosova, E.
DeMoor, R.
Griffith, S.
Thiagarajah, S.
Van Solingen-Ristea, R.
Crauwels, H.
Ford, S.
Patel, P.
Cutrell, A.
Smith, K.
Vandermeulen, K.
Margolis, D.
St Clair, M.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 10 - 12
[4] A combination of viral and participant factors influence virological outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M Phase 3 studies
Patel, Parul
Schapiro, Jonathan
Perno, Carlo
Kuritzkes, Daniel
Cutrell, Amy
Dorey, David
Wang, Yongwei
Van Eygen, Veerle
Crauwels, Herta
Ford, Susan
Talarico, Christine
St Clair, Marty
Jeffrey, Jerry
Vandermeulen, Kati
Spreen, William
Van Lunzen, Jan
HIV MEDICINE, 2021, 22 : 26 - 27
[5] A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies
Margolis, D.
Schapiro, J.
Perno, C.
Kuritzkes, D.
Quercia, R.
Patel, P.
Polli, J.
Cutrell, A.
Dorey, D.
Wang, Y.
Wu, S.
van Eygen, V.
Crauwels, H.
Ford, S.
Baker, M.
Talarico, C.
St Clair, M.
Jeffrey, J.
White, C.
Vanveggel, S.
Van Solingen-Ristea, R.
Vandermeulen, K.
Spreen, W.
van Lunzen, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 15 - 16
[6] Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results
D'Amico, Ronald
Orkin, Chloe
Bernal Morell, Enrique
Tan, Darrell H. S.
Katner, Harold
Singh, Yashna
Stellbrink, Hans-Juergen
Belonosova, Elena
DeMoor, Rebecca
Griffith, Sandy
Thiagarajah, Shanker
Van Solingen-Ristea, Rodica
Crauwels, Herta
Ford, Susan L.
Patel, Parul
Cutrell, Amy
Smith, Kimberly Y.
Vandermeulen, Kati
Margolis, David A.
St Clair, Marty
Spreen, William R.
Finkenzeller, Teresa
INFECTION, 2021, 49 (SUPPL 1) : S7 - S7
[7] Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir plus rilpivirine in the phase IIIb ATLAS-2M study
Chounta, V.
Overton, E.
Noe, S.
Swindells, S.
Negredo, E.
D'Amico, R.
Harrington, C.
Vanveggel, S.
Van Solingen-Ristea, R.
Wang, Y.
Acuipil, C.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 72 - 73
[8] Week 96 efficacy and safety of cabotegravir plus rilpivirine every 2 months in ATLAS-2M Phase IIIb study
Jaeger, Hans
Overton, Edgar
Richmond, Gary
Rizzardini, Giuliano
Andrade-Villanueva, Jaime-Federico
Mngqibisa, Rosie
Hermida, Antonio Ocampo
Thalme, Anders
Benn, Paul
Wang, Yuanyuan
Hudson, Krischan
Margolis, David
Talarico, Christine
Vandermeulen, Kati
Spreen, William
HIV MEDICINE, 2021, 22 : 27 - 28
[9] Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results
Benn, P.
Quercia, R.
Hudson, K.
Wang, Y.
Chounta, V.
Talarico, C.
Ford, S.
Cutrell, A.
Margolis, D.
Van Solingen-Ristea, R.
Vanveggel, S.
Van Eygen, V.
Polli, J.
de Ruiter, A.
Smith, K.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 28 - 29
[10] Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)
Chounta, V.
Wu, S.
Upadhyay, O.
Griffith, S.
Harrington, C.
Orkin, C.
Swindells, S.
Spreen, W.
Margolis, D.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 24 - 24

← 1 2 3 →